Modeling neoadjuvant treatment plus additional therapy effects on US population breast cancer mortality

Clicks: 6
ID: 338745
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #407 of 411 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 411 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Neoadjuvant therapy provides assessment of therapeutic response and the opportunity to guide additional post-surgical adjuvant treatment (NAPAT) for women with residual breast cancer. This treatment approach may reduce breast cancer mortality compared with adjuvant therapy or neoadjuvant treatment without added response-guided therapy (No NAPAT). However, the benefit of this approach has not been quantified in the US population. METHODS: We used six well-established Cancer Intervention and Surveillance Network (CISNET) models to assess the potential impact of NAPAT vs. No NAPAT for women eligible for chemotherapy on breast-cancer mortality from 2018-2030 in the US. We simulated multiple US female birth-cohorts using common screening and treatment inputs derived from clinical trials, large national observational studies and national cancer registries. For years post-2018, we assumed trends in treatments and screening continued as in 2018. Results are presented as a mean and range across models for overall and molecular subtype-specific breast cancer mortality. RESULTS: The models projected that use of neoadjuvant plus additional adjuvant therapy could decrease breast cancer mortality rates to 23.0/100,000 by year 2030 (range across models 20.6-25.4), equaling a 10.5% (6.5%-14.0%) reduction in mortality compared with No NAPAT. Reductions varied by molecular subtype: 30.7% (18.5-38.1%) for women with triple negative tumors, 27.9% (15.6-34.3%) for ER-negative/HER2-positive tumors, 15.4% (10.8-23.6%) for ER-positive/HER2-positive, and essentially no effect 1.3% (-1.0 ̶ 4.0%) for ER-positive/HER2-negative tumors. CONCLUSION: Among women eligible for chemotherapy, use of neoadjuvant plus adjuvant therapy could decrease overall US breast-cancer mortality, even with no further therapeutic advances.
Reference Key
openalex_W7225234009 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Xuelin Huang, Yisheng Li, Swarnavo Sarkar, Sawal Acharya, Hui Huang, Rick Groeneweg, Eugenio Gil Quessep, Nicole Lipa, Juhee Song, Yuanliang Yang, Liyang Sun, Ying Lü, Harald Weedon‐Fekjær, Kathryn P. Lowry, Christina Hunter Chapman, Jinani C. Jayasekera, Clyde B. Schechter, Harry J. de Koning, Brandy M. Heckman‐Stoddard, Natasha K. Stout, Sandra J Lee, Nicolien T. van Ravesteyn, Oğuzhan Alagöz, Allison W. Kurian, Sylvia K. Plevritis, Amy Trentham‐Dietz, Jennifer Lee Caswell-Jin, Jeanne S. Mandelblatt, Donald A. Berry
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag413
URL
https://doi.org/10.1093/jnci/djag413
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.